Prasugrel versus Clopidogrel for Acute Coronary Syndromes without Revascularization

Simple item page
dc.contributor.authorRoe, Matthew T.
dc.contributor.authorArmstrong, Paul W.
dc.contributor.authorFox, Keith A. A.
dc.contributor.authorWhite, Harvey D.
dc.contributor.authorPrabhakaran, Dorairaj
dc.contributor.authorGoodman, Shaun G.
dc.contributor.authorCornel, Jan H.
dc.contributor.authorBhatt, Deepak L.
dc.contributor.authorClemmensen, Peter
dc.contributor.authorMartinez, Felipe
dc.contributor.authorArdissino, Diego
dc.contributor.authorNicolau, Jose C.
dc.contributor.authorBoden, William E.
dc.contributor.authorGurbel, Paul A.
dc.contributor.authorRuzyllo, Witold
dc.contributor.authorDalby, Anthony J.
dc.contributor.authorMcGuire, Darren K.
dc.contributor.authorLeiva Pons, Jose L.
dc.contributor.authorParkhomenko, Alexander
dc.contributor.authorGottlieb, Shmuel
dc.contributor.authorTopacio, Gracita O.
dc.contributor.authorHamm, Christian
dc.contributor.authorPavlides, Gregory
dc.contributor.authorGoudev, Assen R.
dc.contributor.authorOto, Ali
dc.contributor.authorTseng, Chuen Den
dc.contributor.authorMerkely, Bela
dc.contributor.authorGasparovic, Vladimir
dc.contributor.authorCorbalan, Ramon
dc.contributor.authorCinteza, Mircea
dc.contributor.authorMcLendon, R. Craig
dc.contributor.authorWinters, Kenneth J.
dc.contributor.authorBrown, Eileen B.
dc.contributor.authorLokhnygina, Yuliya
dc.contributor.authorAylward, Philip E.
dc.contributor.authorHuber, Kurt
dc.contributor.authorHochman, Judith S.
dc.contributor.authorOhman, E. Magnus
dc.contributor.authorTRILOGY ACS Investigators
dc.date.accessioned2024-01-10T13:52:19Z
dc.date.available2024-01-10T13:52:19Z
dc.date.issued2012
dc.description.abstractBackground
dc.description.abstractThe effect of intensified platelet inhibition for patients with unstable angina or myocardial infarction without ST-segment elevation who do not undergo revascularization has not been delineated.
dc.description.abstractMethods
dc.description.abstractIn this double-blind, randomized trial, in a primary analysis involving 7243 patients under the age of 75 years receiving aspirin, we evaluated up to 30 months of treatment with prasugrel (10 mg daily) versus clopidogrel (75 mg daily). In a secondary analysis involving 2083 patients 75 years of age or older, we evaluated 5 mg of prasugrel versus 75 mg of clopidogrel.
dc.description.abstractResults
dc.description.abstractAt a median follow-up of 17 months, the primary end point of death from cardiovascular causes, myocardial infarction, or stroke among patients under the age of 75 years occurred in 13.9% of the prasugrel group and 16.0% of the clopidogrel group (hazard ratio in the prasugrel group, 0.91; 95% confidence interval [CI], 0.79 to 1.05; P = 0.21). Similar results were observed in the overall population. The prespecified analysis of multiple recurrent ischemic events (all components of the primary end point) suggested a lower risk for prasugrel among patients under the age of 75 years (hazard ratio, 0.85; 95% CI, 0.72 to 1.00; P = 0.04). Rates of severe and intracranial bleeding were similar in the two groups in all age groups. There was no significant between-group difference in the frequency of nonhemorrhagic serious adverse events, except for a higher frequency of heart failure in the clopidogrel group.
dc.description.abstractConclusions
dc.description.abstractAmong patients with unstable angina or myocardial infarction without ST- segment elevation, prasugrel did not significantly reduce the frequency of the primary end point, as compared with clopidogrel, and similar risks of bleeding were observed. (Funded by Eli Lilly and Daiichi Sankyo; TRILOGY ACS ClinicalTrials.gov number, NCT00699998.)
dc.description.funderEli Lilly
dc.description.funderDaiichi Sankyo
dc.fechaingreso.objetodigital2024-04-25
dc.format.extent13 páginas
dc.fuente.origenWOS
dc.identifier.doi10.1056/NEJMoa1205512
dc.identifier.eissn1533-4406
dc.identifier.issn0028-4793
dc.identifier.pubmedidMEDLINE:22920930
dc.identifier.urihttps://doi.org/10.1056/NEJMoa1205512
dc.identifier.urihttps://repositorio.uc.cl/handle/11534/79656
dc.identifier.wosidWOS:000309406100006
dc.information.autorucMedicina;Corbalan R;S/I;98700
dc.issue.numero14
dc.language.isoen
dc.nota.accesocontenido parcial
dc.pagina.final1309
dc.pagina.inicio1297
dc.publisherMASSACHUSETTS MEDICAL SOC
dc.revistaNEW ENGLAND JOURNAL OF MEDICINE
dc.rightsacceso restringido
dc.subjectMYOCARDIAL-INFARCTION
dc.subjectMEDICAL-MANAGEMENT
dc.subjectOUTCOMES
dc.subjectPREDICTORS
dc.subjectSTRATEGY
dc.subject.ods03 Good Health and Well-being
dc.subject.odspa03 Salud y bienestar
dc.titlePrasugrel versus Clopidogrel for Acute Coronary Syndromes without Revascularization
dc.typeartículo
dc.volumen367
sipa.codpersvinculados98700
sipa.indexWOS
sipa.indexScopus
sipa.trazabilidadCarga SIPA;09-01-2024
Files
Original bundle
Now showing 1 - 1 of 1
Thumbnail Image
Name:
2024-04-25. Prasugrel versus Clopidogrel for Acute Coronary Syndromes without Revascularization.pdf
Size:
3.23 KB
Format:
Adobe Portable Document Format
Description:
Download
Collections
Artículos de revistas